Thomas McFarland

535 total citations
21 papers, 401 citations indexed

About

Thomas McFarland is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas McFarland has authored 21 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas McFarland's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and CAR-T cell therapy research (4 papers). Thomas McFarland is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and CAR-T cell therapy research (4 papers). Thomas McFarland collaborates with scholars based in United States and United Kingdom. Thomas McFarland's co-authors include Jae Werndli, Jens C. Eickhoff, Brad S. Kahl, Jules H. Blank, Walter Longo, Howard H. Bailey, Wayne A. Bottner, Chris Jones, James L. Zehnder and Barry G.W. Arnason and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Thomas McFarland

21 papers receiving 388 citations

Peers

Countries citing papers authored by Thomas McFarland

Since Specialization

Citations

This map shows the geographic impact of Thomas McFarland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas McFarland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas McFarland more than expected).

Fields of papers citing papers by Thomas McFarland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas McFarland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas McFarland. The network helps show where Thomas McFarland may publish in the future.

Co-authorship network of co-authors of Thomas McFarland

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas McFarland. A scholar is included among the top collaborators of Thomas McFarland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas McFarland. Thomas McFarland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma 2018 ·Cancer Immunology Immunotherapy ·Mark R. Albertini, Richard K. Yang, Erik A. Ranheim, Jacquelyn A. Hank, Cindy Zuleger, Sharon M. Weber, Heather B. Neuman, (unknown), Tracey L. Weigel, (unknown), (unknown), (unknown), Thomas McFarland, Jacek Gan, Lakeesha Carmichael, KyungMann Kim, Hans Loibner, Stephen D. Gillies, Paul M. Sondel	36
2	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Elizabeth Chang, Lakeesha Carmichael, KyungMann Kim, Christopher G. Peterson, David T. Yang, Anne M. Traynor, Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	11
3	Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma 2016 ·Cancer Immunology Immunotherapy ·Mark R. Albertini, Erik A. Ranheim, Cindy Zuleger, Paul M. Sondel, Jacquelyn A. Hank, Alan J. Bridges, Michael A. Newton, Thomas McFarland, Jennifer Collins, (unknown), (unknown), Heather B. Neuman, Sharon M. Weber, Giles F. Whalen, Uri Galili	14
4	A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas 2016 ·Annals of Oncology ·Mark Agulnik, Ricardo Costa, Mohammed Milhem, Alfred Rademaker, (unknown), David Daniels, (unknown), Catherine Humphreys, (unknown), Lauren Nye, (unknown), (unknown), (unknown), Thomas McFarland, Keith M. Skubitz, Steven I. Robinson, Scott H. Okuno, Brian Andrew Van Tine	23
5	Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study 2016 ·Blood ·Julie Chang, Christopher G. Peterson, Lakeesha Carmichael, KyungMann Kim, David T. Yang, Anne M. Traynor, Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	2
6	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma 2015 ·Rare Tumors ·Steven Attia, Scott H. Okuno, Steven I. Robinson, (unknown), Daniel J. Indelicato, Robin L. Jones, Sanjay P. Bagaria, (unknown), Kevin R. Kozak, Cherise Cortese, Thomas McFarland, (unknown), Robert G. Maki	30
7	A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. 2014 ·Journal of Clinical Oncology ·Mark R. Albertini, Erik A. Ranheim, Jacquelyn A. Hank, Cindy Zuleger, Thomas McFarland, Jennifer Collins, (unknown), Sharon M. Weber, Tracey L. Weigel, Heather B. Neuman, Gregory K. Hartig, (unknown), (unknown), Jacek Gan, Richard K. Yang, KyungMann Kim, Stephen D. Gillies, Paul M. Sondel	2
8	A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer 2011 ·Urologic Oncology Seminars and Original Investigations ·Jeremy Cetnar, George Wilding, Douglas G. McNeel, Noelle K. LoConte, Thomas McFarland, Jens C. Eickhoff, Glenn Liu	11
9	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network 2011 ·Leukemia & lymphoma ·Vaishalee P. Kenkre, (unknown), Jens C. Eickhoff, Jules H. Blank, Thomas McFarland, Wayne A. Bottner, (unknown), Jae Werndli, Howard H. Bailey, Brad S. Kahl	30
10	VcR‐CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study 2011 ·British Journal of Haematology ·Elizabeth Chang, Christopher G. Peterson, Sangbum Choi, Jens C. Eickhoff, KyungMann Kim, David T. Yang, (unknown), (unknown), Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	43
11	Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies 2008 ·Cancer Chemotherapy and Pharmacology ·Steven Attia, (unknown), Kyle D. Holen, Howard H. Bailey, Jens C. Eickhoff, William R. Schelman, Anne M. Traynor, Daniel Mulkerin, Toby C. Campbell, Thomas McFarland, (unknown), James F. Cleary, Amyé Tevaarwerk, Dona Alberti, George Wilding, Glenn Liu	4
12	VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network 2008 ·Blood ·Brad S. Kahl, Julie Chang, Jens C. Eickhoff, (unknown), (unknown), Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Christopher G. Peterson	14
13	A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma 2007 ·Journal of Clinical Oncology ·Brad S. Kahl, Christopher G. Peterson, Jules H. Blank, Thomas McFarland, (unknown), Jens C. Eickhoff, Jae Werndli, Natalie S. Callander, T.G. Myers	4
14	Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM). 2007 ·Blood ·(unknown), Stephanie Markovina, Shigeki Miyamoto, Walter Longo, Eliot C. Williams, Thomas McFarland, Jae Werndli, Elisabeth Wagner, Mark Juckett, Natalie S. Callander	13
15	Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network 2006 ·Annals of Oncology ·Brad S. Kahl, Walter Longo, Jens C. Eickhoff, James L. Zehnder, Chris Jones, Jules H. Blank, Thomas McFarland, Wayne A. Bottner, (unknown), Jae Werndli, Howard H. Bailey	82
16	A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma 2005 ·Oncology ·(unknown), Daniel Mulkerin, Jordan Berlin, KyungMann Kim, Howard H. Bailey, Thomas J. Saphner, (unknown), Richard M. Hansen, Harish G. Ahuja, Thomas McFarland, James P. Thomas	9
17	Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. 2004 ·Blood ·Brad S. Kahl, (unknown), Jules H. Blank, Anthony J. Jaslowski, (unknown), Wayne A. Bottner, (unknown), Thomas McFarland, (unknown), (unknown), Emily A. Stevens, Jens C. Eickhoff, Walter Longo	9
18	CD43 diminishes susceptibility to T lymphocyte-mediated cytolysis. 1995 ·The Journal of Immunology ·Thomas McFarland, Blair Ardman, N. Manjunath, (unknown), Judy Lieberman	15
19	Reduced incidence and severity of accelerated graft atherosclerosis in cardiac transplant recipients treated with prophylactic antilymphocyte globulin. 1993 ·PubMed ·(unknown), (unknown), (unknown), Thomas McFarland, (unknown), (unknown), (unknown), (unknown), (unknown)	6
20	Low T8 antigen density on lymphocytes in active multiple sclerosis 1984 ·Annals of Neurology ·Anthony T. Reder, Jack P. Antel, Joël Oger, Thomas McFarland, (unknown), Barry G.W. Arnason	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact